Camilla Fowst

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen et al. · New England Journal of Medicine · 2019 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +6

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations

Medicine, Oncology, Pharmacology +17

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles, Se Hoon Park, Éric Voog et al. · New England Journal of Medicine · 2020 · 1.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Richard S. Finn, Judy Dering, Dylan Conklin et al. · Breast Cancer Research · 2009 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial

Manfred Kaufmann, Emilio Bajetta, Luc Dirix et al. · Journal of Clinical Oncology · 2000 · 525 citations

Medicine, Oncology, Pharmacology +14